Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
62.1M
-
Number of holders
-
240
-
Total 13F shares, excl. options
-
63.3M
-
Shares change
-
+1.62M
-
Total reported value, excl. options
-
$2.44B
-
Value change
-
+$43.6M
-
Put/Call ratio
-
0.97
-
Number of buys
-
130
-
Number of sells
-
-113
-
Price
-
$38.60
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q4 2024
290 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q4 2024.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 240 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.3M shares
.
Largest 10 shareholders include BlackRock, Inc. (9.88M shares), FARALLON CAPITAL MANAGEMENT LLC (5.93M shares), RTW INVESTMENTS, LP (5.5M shares), VANGUARD GROUP INC (4.22M shares), STATE STREET CORP (3.33M shares), JOHNSON & JOHNSON (2.45M shares), BVF INC/IL (1.9M shares), Pacer Advisors, Inc. (1.88M shares), Jefferies Financial Group Inc. (1.49M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.39M shares).
This table shows the top 240 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.